{"parse":{"title":"Qiagen","pageid":3283783,"revid":847903468,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"plainlinks metadata ambox ambox-content ambox-multiple_issues compact-ambox\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/40px-Ambox_important.svg.png\" width=\"40\" height=\"40\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/60px-Ambox_important.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/80px-Ambox_important.svg.png 2x\" data-file-width=\"40\" data-file-height=\"40\" /></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\"><div class=\"mw-collapsible\" style=\"width:95%; margin: 0.2em 0;\"><b>This article has multiple issues.</b> Please help <b><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Qiagen&amp;action=edit\">improve it</a></b> or discuss these issues on the <b><a href=\"/wiki/Talk:Qiagen\" title=\"Talk:Qiagen\">talk page</a></b>. <small><i>(<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove these template messages</a>)</i></small>\n<div class=\"mw-collapsible-content\" style=\"margin-top: 0.3em;\">\n      <table class=\"plainlinks metadata ambox ambox-content ambox-Advert\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/40px-Ambox_important.svg.png\" width=\"40\" height=\"40\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/60px-Ambox_important.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/80px-Ambox_important.svg.png 2x\" data-file-width=\"40\" data-file-height=\"40\" /></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This article <b>contains content that is written like <a href=\"/wiki/Wikipedia:What_Wikipedia_is_not#Wikipedia_is_not_a_soapbox_or_means_of_promotion\" title=\"Wikipedia:What Wikipedia is not\">an advertisement</a></b>.<span class=\"hide-when-compact\"> Please help <a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Qiagen&amp;action=edit\">improve it</a> by removing <a href=\"/wiki/Wikipedia:Spam\" title=\"Wikipedia:Spam\">promotional content</a> and inappropriate <a href=\"/wiki/Wikipedia:External_links\" title=\"Wikipedia:External links\">external links</a>, and by adding encyclopedic content written from a <a href=\"/wiki/Wikipedia:Neutral_point_of_view\" title=\"Wikipedia:Neutral point of view\">neutral point of view</a>.</span>  <small><i>(November 2010)</i></small><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n<table class=\"plainlinks metadata ambox ambox-content ambox-Refimprove\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><a href=\"/wiki/File:Question_book-new.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png\" width=\"50\" height=\"39\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/75px-Question_book-new.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/100px-Question_book-new.svg.png 2x\" data-file-width=\"512\" data-file-height=\"399\" /></a></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This article <b>needs additional citations for <a href=\"/wiki/Wikipedia:Verifiability\" title=\"Wikipedia:Verifiability\">verification</a></b>.<span class=\"hide-when-compact\"> Please help <a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Qiagen&amp;action=edit\">improve this article</a> by <a href=\"/wiki/Help:Introduction_to_referencing_with_Wiki_Markup/1\" title=\"Help:Introduction to referencing with Wiki Markup/1\">adding citations to reliable sources</a>. Unsourced material may be challenged and removed.</span>  <small><i>(May 2011)</i></small><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n    </div>\n</div><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n<table class=\"infobox vcard\" style=\"width:22em\"><caption class=\"fn org\">QIAGEN N.V.</caption><tbody><tr><td colspan=\"2\" class=\"logo\" style=\"text-align:center\">\n<a href=\"/wiki/File:Qiagen.svg\" class=\"image\"><img alt=\"Qiagen.svg\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/7/7d/Qiagen.svg/130px-Qiagen.svg.png\" width=\"130\" height=\"110\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/7/7d/Qiagen.svg/195px-Qiagen.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/7/7d/Qiagen.svg/260px-Qiagen.svg.png 2x\" data-file-width=\"188\" data-file-height=\"159\" /></a></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\"><div style=\"padding:0.1em 0;line-height:1.2em;\"><a href=\"/wiki/List_of_business_entities\" class=\"mw-redirect\" title=\"List of business entities\">Type</a></div></th><td class=\"category\" style=\"line-height:1.35em;\">\n<a href=\"/wiki/Naamloze_vennootschap\" title=\"Naamloze vennootschap\">Naamloze vennootschap</a></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\"><a href=\"/wiki/Ticker_symbol\" title=\"Ticker symbol\">Traded&#160;as</a></th><td style=\"line-height:1.35em;\">\n<a href=\"/wiki/New_York_Stock_Exchange\" title=\"New York Stock Exchange\">NYSE</a>:&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.nyse.com/quote/XNYS:QGEN\">QGEN</a><br /><a href=\"/wiki/Frankfurt_Stock_Exchange\" title=\"Frankfurt Stock Exchange\">FWB</a>:&#160;<a rel=\"nofollow\" class=\"external text\" href=\"http://www.boerse-frankfurt.de/en/equities/search/result?name_isin_wkn=QIA\">QIA</a><br /><a href=\"/wiki/Russell_1000_Index\" title=\"Russell 1000 Index\">Russell 1000 Component</a></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\">Industry</th><td class=\"category\" style=\"line-height:1.35em;\">\n<a href=\"/wiki/Biotechnology\" title=\"Biotechnology\">Biotechnology</a></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\">Founded</th><td style=\"line-height:1.35em;\">\nNovember&#160;29, 1984<span class=\"noprint\">&#59;&#32;33 years ago</span><span style=\"display:none\">&#160;(<span class=\"bday dtstart published updated\">1984-11-29</span>)</span></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\">Headquarters</th><td class=\"label\" style=\"line-height:1.35em;\">\n<a href=\"/wiki/Venlo\" title=\"Venlo\">Venlo</a>, <a href=\"/wiki/Netherlands\" title=\"Netherlands\">Netherlands</a> <small>(corporate)</small>; <a href=\"/wiki/Hilden\" title=\"Hilden\">Hilden</a> (near <a href=\"/wiki/D%C3%BCsseldorf\" title=\"D\u00fcsseldorf\">D\u00fcsseldorf</a>), <a href=\"/wiki/Germany\" title=\"Germany\">Germany</a> <small>(operational)</small></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\"><div style=\"padding:0.1em 0;line-height:1.2em;\">Key people</div></th><td class=\"agent\" style=\"line-height:1.35em;\">\n<a href=\"/wiki/Peer_M._Schatz\" title=\"Peer M. Schatz\">Peer Schatz</a> <small>(<a href=\"/wiki/Chief_executive_officer\" title=\"Chief executive officer\">CEO</a> and chairman of the management board)</small>, Prof. Dr. Manfred Karobath <sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup> <small>(<a href=\"/wiki/Chairman\" title=\"Chairman\">Chairman</a> of the <a href=\"/wiki/Supervisory_board\" title=\"Supervisory board\">supervisory board</a>)</small></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\">Revenue</th><td style=\"line-height:1.35em;\">\nUS $1.417.536 billion <small>(2017)</small> <sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\"><div style=\"padding:0.1em 0;line-height:1.2em;\"><a href=\"/wiki/Earnings_before_interest_and_taxes\" title=\"Earnings before interest and taxes\">Operating income</a></div></th><td style=\"line-height:1.35em;\">\nUS $371.5 million <small>(2017 adjusted, excluding restructuring charge)</small> <sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\"><span class=\"nowrap\"><a href=\"/wiki/Asset\" title=\"Asset\">Total assets</a></span></th><td style=\"line-height:1.35em;\">\nUS $5.038.516 billion <small>(end of December 2017)</small> <sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\"><span class=\"nowrap\"><a href=\"/wiki/Equity_(finance)\" title=\"Equity (finance)\">Total equity</a></span></th><td style=\"line-height:1.35em;\">\nUS $2.540.996 billion <small>(end of December 2017)</small> <sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\"><div style=\"padding:0.1em 0;line-height:1.2em;\">Number of employees</div></th><td style=\"line-height:1.35em;\">\nabout 4,700 <small>(end of December 2017)</small> <sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\">Website</th><td style=\"line-height:1.35em;\">\n<span class=\"url\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.qiagen.com\">www<wbr />.qiagen<wbr />.com</a></span></td></tr></tbody></table>\n<p><b>QIAGEN</b> is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding QIAGEN N.V., the company operates more than 35 offices in over 25 countries.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup> QIAGEN\u2019s shares are listed at the <a href=\"/wiki/NYSE\" class=\"mw-redirect\" title=\"NYSE\">NYSE</a> (using ticker QGEN) and at the <a href=\"/wiki/Frankfurt_Stock_Exchange\" title=\"Frankfurt Stock Exchange\">Frankfurt Stock Exchange</a> in the Prime Standard (using ticker QIA). <a href=\"/wiki/Peer_M._Schatz\" title=\"Peer M. Schatz\">Peer M. Schatz</a> is the company\u2019s chief executive officer. The main operative headquarters are located in <a href=\"/wiki/Hilden\" title=\"Hilden\">Hilden</a>, <a href=\"/wiki/Germany\" title=\"Germany\">Germany</a>.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#History\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">History</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#1984-2000\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">1984-2000</span></a></li>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#2001-present\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">2001-present</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Products\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Products</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Application_areas\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Application areas</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#Molecular_diagnostics\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">Molecular diagnostics</span></a></li>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Applied_testing\"><span class=\"tocnumber\">3.2</span> <span class=\"toctext\">Applied testing</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#Academic_research\"><span class=\"tocnumber\">3.3</span> <span class=\"toctext\">Academic research</span></a></li>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#Pharmaceutical_industry\"><span class=\"tocnumber\">3.4</span> <span class=\"toctext\">Pharmaceutical industry</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#Management\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Management</span></a></li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#Structure_of_the_company\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Structure of the company</span></a></li>\n<li class=\"toclevel-1 tocsection-12\"><a href=\"#References\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=1\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"1984-2000\">1984-2000</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=2\" title=\"Edit section: 1984-2000\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In 1984,  QIAGEN was established on November 29 by a team of scientists at the <a href=\"/wiki/University_of_D%C3%BCsseldorf\" title=\"University of D\u00fcsseldorf\">Heinrich Heine University D\u00fcsseldorf, Germany</a>. Two years later, QIAGEN launched its first product, a kit for purification of plasmids \u2013 small ring-shaped <a href=\"/wiki/DNA\" title=\"DNA\">DNA</a> molecules in bacterial cells \u2013 cutting the preparation time for <a href=\"/wiki/Plasmid\" title=\"Plasmid\">plasmids</a> from between two and three days down to two hours.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup> 1996 saw the initial public offering of QIAGEN on the technology-oriented <a href=\"/wiki/NASDAQ\" title=\"NASDAQ\">Nasdaq</a> stock exchange, becoming the first German company to do so.<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup> 1997 saw the initial public offering on the <a href=\"/wiki/Frankfurt_Stock_Exchange\" title=\"Frankfurt Stock Exchange\">Frankfurt Stock Exchange</a> in Germany.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"2001-present\">2001-present</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=3\" title=\"Edit section: 2001-present\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In 2004, QIAGEN acquired key assets of Molecular Staging, Inc. Two years later, QIAGEN established its Asia regional headquarters in Shanghai. In 2007 sales reached US$649.8 million and the number of employees surpassed 2,600. Qiagen acquired <a href=\"/wiki/Digene\" title=\"Digene\">Digene</a> for US$1.6 billion, furthering QIAGEN in  molecular diagnostics by revenue and diagnostics for disease prevention.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p><p>In 2009, QIAGEN began building its Personalized Healthcare business through the acquisition of DxS Ltd, in a deal valued at US$95 million<sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup> and it acquired SABiosciences Corp. in a deal valued at US$9 million.<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup>  At the end of 2009 QIAGEN surpassed the US$1 billion revenue mark and had over 3,500 employees. QIAGEN became one of the first companies to release a clinically verified diagnostic test for the detection of <a href=\"/wiki/2009_flu_pandemic\" title=\"2009 flu pandemic\">H1N1</a>, more commonly known as Swine Flu.<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup>\n</p><p>In 2010 QIAGEN acquired ESE GmbH,<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup> giving the company access to point of need testing devices for the application of molecular diagnostic tests without laboratory infrastructure. QIAGEN launched the QIAsymphony AS and QIAsymphony RGQ platforms, adding to the company\u2019s portfolio for laboratory workflow automation and molecular test full-process automation respectively.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p><p>In 2011 QIAGEN acquired Ipsogen S.A. for US$101 million,<sup id=\"cite_ref-ipsogen_13-0\" class=\"reference\"><a href=\"#cite_note-ipsogen-13\">&#91;13&#93;</a></sup><sup id=\"cite_ref-analyticalworld2011_14-0\" class=\"reference\"><a href=\"#cite_note-analyticalworld2011-14\">&#91;14&#93;</a></sup> adding to the company\u2019s product and IP portfolio in the blood cancer space and developing its position in molecular diagnostics for oncology. QIAGEN also acquired Cellestis Limited for US$374 million,<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup> giving the company access to QuantiFERON technology for disease detection and prevention. The company added two new offices in the Asia Pacific region in <a href=\"/wiki/New_Delhi\" title=\"New Delhi\">New Delhi</a>, <a href=\"/wiki/India\" title=\"India\">India</a> and <a href=\"/wiki/Taipei\" title=\"Taipei\">Taipei</a>, <a href=\"/wiki/Taiwan\" title=\"Taiwan\">Taiwan</a>. The company announced a comprehensive restructuring program to focus on high-growth areas such as personalized medicine and business in emerging markets. The program includes workforce reduction and internal restructuring affecting approximately 10% of the company\u2019s 3,900 positions.<sup id=\"cite_ref-streetinsider2011_16-0\" class=\"reference\"><a href=\"#cite_note-streetinsider2011-16\">&#91;16&#93;</a></sup>\n</p><p>In 2013, QIAGEN acquired Ingenuity Systems.<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup> QIAGEN also acquired <a href=\"/wiki/CLC_bio\" title=\"CLC bio\">CLC bio</a>, which offers bioinformatics analysis software.<sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup> In 2015, QIAGEN acquired AdnaGen\u2019s circulating tumor cell enrichment technology.<sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup> Qiagen also acquired Enzymatics enzyme solutions.<sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup> On March 2015, a<a href=\"/wiki/Management_buyout\" title=\"Management buyout\">management buyout</a> of QIAGEN Marseille led to the creation of HalioDx.<sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup> In late 2015 the GeneReader NGS System was launched.<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup> In 2016 QIAGEN acquired the Danish molecular diagnostics company Exiqon.<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup>\n</p><p>In 2018 QIAGEN transferred listing to New York Stock Exchange.<sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup> In April 2018, QIAGEN acquired the Spanish firm STAT-Dx and launched the QIAstat-Dx molecular diagnostics platform, developed by STAT-Dx for analysis of complex disease syndromes, at the European Congress of Clinical Microbiology and Infectious Diseases.<sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Products\">Products</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=4\" title=\"Edit section: Products\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">For QIAGEN columns, see <a href=\"/wiki/Column-based_nucleic_acid_purification\" class=\"mw-redirect\" title=\"Column-based nucleic acid purification\">column-based nucleic acid purification</a>.</div>\n<p>QIAGEN is a worldwide provider of molecular sample and assay technologies. Sample technologies are used to collect samples of tissue, fluids, etc. and stabilize, extract and purify various molecules of interest such as <a href=\"/wiki/DNA\" title=\"DNA\">DNA</a>, <a href=\"/wiki/RNA\" title=\"RNA\">RNA</a> or <a href=\"/wiki/Proteins\" class=\"mw-redirect\" title=\"Proteins\">proteins</a> from other cellular components. Assay technologies are then used to amplify (multiply) and enrich this small amount of isolated material to make it visible, readable and ready for interpretation. The separation and purification of genetic information is a basic precondition for further application or analysis.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p><p>QIAGEN provides molecular technologies offered as kits with open or specific target analytes. According to QIAGEN, the company\u2019s current portfolio covers more than 500 products and more than 2,000 patents and licenses.<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup>\n</p><p>In 2014, QIAGEN entered into a <a href=\"/wiki/Supply_agreement\" class=\"mw-redirect\" title=\"Supply agreement\">supply agreement</a> with Trinean for the manufacture of a QIAGEN-branded \"micro-volume\" <a href=\"/wiki/Spectrophotometer\" class=\"mw-redirect\" title=\"Spectrophotometer\">spectrophotometer</a>, to be sold under the name \"QIAxpert\".<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Application_areas\">Application areas</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=5\" title=\"Edit section: Application areas\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Until the mid-2000s, QIAGEN was mainly a provider of sample technologies for the academic research market. QIAGEN's current product portfolio includes sample and assay technologies, specific automation solutions, and a bioinformatics analysis portfolio in 4 markets.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Molecular_diagnostics\">Molecular diagnostics</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=6\" title=\"Edit section: Molecular diagnostics\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Molecular diagnostics detect the nucleic acids (DNA and RNA) of target diseases or pathogens in samples such as  blood or tissue. These procedures can help to detect viruses and bacteria more rapidly and with greater sensitivity and specificity than other methods such as bacterial culture or immunodiagnostics.<sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup> Molecular diagnostics are also used to analyze individual patient's genomic information to further classify certain diseases and to determine the most appropriate treatment. QIAGEN\u2019s portfolio in molecular diagnostics covers various applications which the company divides into three main segments:<sup id=\"cite_ref-29\" class=\"reference\"><a href=\"#cite_note-29\">&#91;29&#93;</a></sup>\n</p><p>\u2022 Oncology: The company\u2019s portfolio in oncology includes tests for a broad range of clinically relevant biomarkers, particularly in cancer, encompassing companion diagnostics that are marketed in combination with certain drugs, helping to guide treatment decisions. In addition, QIAGEN markets a range of gene panels for research applications in next-generation sequencing, covering dozens of genes associated with various cancers. Furthermore, the company offers technologies for the extraction and enrichment of molecular biomarkers from body fluids, supporting the development of liquid biopsies. Minimally invasive liquid biopsies hold promise to transform the diagnosis and treatment of cancer.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p><p>\u2022 Modulation of Immune Response: The QuantiFERON-TB Gold In-Tube Test (QFT) is regarded worldwide as the modern standard for detection of latent tuberculosis infection. According to WHO estimates, this condition affects about one-third of the world\u2019s population. As up to 10% of people with latent TB infection will develop the active disease in the course of their lives, the identification and treatment of at-risk groups with latent TB is important for sustainable control of this potentially life-threatening infectious disease.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p><p>\u2022 Infectious Diseases: QIAGEN offers several comprehensive test panels for detection of bacterial and viral pathogens. The portfolio encompasses assays for the detection of individual pathogens such as Influenza, HIV, Hepatitis, and healthcare-associated infections. The company also has a global leadership position in screening for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Applied_testing\">Applied testing</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=7\" title=\"Edit section: Applied testing\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Applied Testing is the use of molecular biology/diagnostics in practical, non-clinical applications such as veterinary medicine, forensics, food-quality monitoring and protection against biological hazards. QIAGEN's portfolio includes:<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p><p>\u2022 Food safety: tests for pathogens (such as salmonella, legionella and listeria), allergens, genetically modified organisms as well as food origin and quality.\n</p><p>\u2022 Veterinary medicine: tests for pathogens (such as bird flu, for which Qiagen was the first company to offer an approved test) as well as pandemic prevention and monitoring.\n</p><p>\u2022 Forensics: tests used to identify victims, prosecute criminals and determine paternity or lineage.\n</p>\n<h3><span class=\"mw-headline\" id=\"Academic_research\">Academic research</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=8\" title=\"Edit section: Academic research\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The life science research market encompasses all disciplines focusing on living organisms such as humans, animals, plants or bacteria (e.g., biochemistry, biomedicine or genetic engineering). Much of the research is done on a molecular level targeting DNA, RNA and proteins and helps scientists to comprehend basic processes in cells and organisms.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p><p>QIAGEN introduced the first kit for purification of <a href=\"/wiki/Plasmids\" class=\"mw-redirect\" title=\"Plasmids\">plasmids</a> \u2013 small ring-shaped DNA molecules in bacterial cells \u2013 in 1986, cutting the preparation time for plasmids from between two and three days down to two hours. The company has a global market share exceeding 70% for certain sample preparation technologies.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Pharmaceutical_industry\">Pharmaceutical industry</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=9\" title=\"Edit section: Pharmaceutical industry\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Multinational pharmaceutical companies use molecular sample and assay technologies in all phases of the drug development process, from the fundamental pharmaceutical research stage, through preclinical and clinical studies, to the commercialization and application of new products.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p><p>QIAGEN technologies can be used to identify genes that participate in the emergence of diseases, carry out studies on the functions and interactions between genes (or proteins) in entire biological pathways, identify and validate potential biomarkers and identify and evaluate therapeutic target molecules and suitable active agent candidates. QIAGEN's products can also be used in the execution of the clinical studies.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Management\">Management</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=10\" title=\"Edit section: Management\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>As of February 2018, the company's Executive Committee consisted of the following members:<sup id=\"cite_ref-qiagenmgt_30-0\" class=\"reference\"><a href=\"#cite_note-qiagenmgt-30\">&#91;30&#93;</a></sup>\n</p>\n<ul><li><a href=\"/wiki/Peer_M._Schatz\" title=\"Peer M. Schatz\">Peer M. Schatz</a> (Chief Executive Officer)</li>\n<li>Roland Sackers (Chief Financial Officer)</li>\n<li>Dr. Thomas Schweins (Senior Vice President Life Science Business Area)</li>\n<li>Mark Gladwell (Senior Vice President Global Operations)</li>\n<li>Thierry Bernard (Senior Vice President Molecular Diagnostics Business Area)</li>\n<li>Dr. Jonathan Sheldon (Senior Vice President Bioinformatics Business Area)</li>\n<li>Manuel O. Mendez (Senior Vice President Global Commercial Operations)</li>\n<li>Dr. Annette Koch (Senior Vice President Global and Chief Human Resources Officer)</li></ul>\n<h2><span class=\"mw-headline\" id=\"Structure_of_the_company\">Structure of the company</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=11\" title=\"Edit section: Structure of the company\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>QIAGEN has a holding structure. The holding (QIAGEN N.V.) is located in Venlo, <a href=\"/wiki/Netherlands\" title=\"Netherlands\">The Netherlands</a>. The operative and European headquarters are located in Hilden, <a href=\"/wiki/Germany\" title=\"Germany\">Germany</a>. Further regional headquarters are located in <a href=\"/wiki/Maryland\" title=\"Maryland\">Maryland</a> for North America and <a href=\"/wiki/Shanghai\" title=\"Shanghai\">Shanghai</a> for Asia.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Qiagen&amp;action=edit&amp;section=12\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"https://www.qiagen.com/be/about-us/investors/corporate-governance/supervisory-board/\">https://www.qiagen.com/be/about-us/investors/corporate-governance/supervisory-board/</a></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_q4fy2018_results\">https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_q4fy2018_results</a></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\">Adjusted operating income excluding restructuring charges and other items such as business integration, acquisition-related costs, litigation settlements and the amortization of intangible assets acquired in business combinations. <a rel=\"nofollow\" class=\"external free\" href=\"https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_q4fy2018_results\">https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_q4fy2018_results</a></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"https://www.qiagen.com/be/about-us/investors/financial-information/key-figures/\">https://www.qiagen.com/be/about-us/investors/financial-information/key-figures/</a></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"https://www.qiagen.com/be/about-us/investors/financial-information/key-figures/\">https://www.qiagen.com/be/about-us/investors/financial-information/key-figures/</a></span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_q4fy2018_results\">https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_q4fy2018_results</a></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external autonumber\" href=\"http://corporate.qiagen.com/about-us\">[1]</a></span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\">Peter A. Brooke, Daniel Penrice (Nov 10, 2009). <i>A Vision for Venture Capital: Realizing the Promise of Global Venture Capital and Private Equity (Winthrop Group)</i>. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/1584657995\" title=\"Special:BookSources/1584657995\">1584657995</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=A+Vision+for+Venture+Capital%3A+Realizing+the+Promise+of+Global+Venture+Capital+and+Private+Equity+%28Winthrop+Group%29&amp;rft.date=2009-11-10&amp;rft.isbn=1584657995&amp;rft.au=Peter+A.+Brooke%2C+Daniel+Penrice&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.genomeweb.com/dxpgx/qiagen-acquires-uks-dxs-deal-worth-130m\">\"Qiagen Acquires UK's DxS in Deal Worth up to $130M\"</a>. <i>GenomeWeb Daily News</i>. United States: GenomeWeb. 23 September 2009. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20110320104914/http://www.genomeweb.com/dxpgx/qiagen-acquires-uks-dxs-deal-worth-130m\">Archived</a> from the original on 20 March 2011.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=GenomeWeb+Daily+News&amp;rft.atitle=Qiagen+Acquires+UK%27s+DxS+in+Deal+Worth+up+to+%24130M&amp;rft.date=2009-09-23&amp;rft_id=http%3A%2F%2Fwww.genomeweb.com%2Fdxpgx%2Fqiagen-acquires-uks-dxs-deal-worth-130m&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Vence, Tracy (16 December 2009). <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140320033732/http://www.biotechniques.com/news/biotechniquesNews/biotechniques-185334.html\">\"QIAGEN acquires SABiosciences\"</a>. <i><a href=\"/wiki/BioTechniques\" title=\"BioTechniques\">BioTechniques</a></i>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.biotechniques.com/news/biotechniquesNews/biotechniques-185334.html\">the original</a> on 19 March 2014.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BioTechniques&amp;rft.atitle=QIAGEN+acquires+SABiosciences&amp;rft.date=2009-12-16&amp;rft.aulast=Vence&amp;rft.aufirst=Tracy&amp;rft_id=http%3A%2F%2Fwww.biotechniques.com%2Fnews%2FbiotechniquesNews%2Fbiotechniques-185334.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Chengpei, Zhu; Xiaomin, Zhang (12 September 2009). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.chinadaily.com.cn/cndy/2009-09/12/content_8684608.htm\">\"Molecular firm Qiagen releases rapid H1N1 test\"</a>. <i><a href=\"/wiki/ChinaDaily\" class=\"mw-redirect\" title=\"ChinaDaily\">ChinaDaily</a></i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140320034515/http://www.chinadaily.com.cn/cndy/2009-09/12/content_8684608.htm\">Archived</a> from the original on 19 March 2014.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=ChinaDaily&amp;rft.atitle=Molecular+firm+Qiagen+releases+rapid+H1N1+test&amp;rft.date=2009-09-12&amp;rft.aulast=Chengpei&amp;rft.aufirst=Zhu&amp;rft.au=Xiaomin%2C+Zhang&amp;rft_id=http%3A%2F%2Fwww.chinadaily.com.cn%2Fcndy%2F2009-09%2F12%2Fcontent_8684608.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.bionity.com/en/news/111706/qiagen-acquires-ese-gmbh.html\">\"QIAGEN Acquires ESE GmbH\"</a>. News &amp; Events. <i>Bionity</i>. Germany: CHEMIE.DE. 14 January 2010. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140320035423/http://www.bionity.com/en/news/111706/qiagen-acquires-ese-gmbh.html\">Archived</a> from the original on 19 March 2014.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bionity&amp;rft.atitle=QIAGEN+Acquires+ESE+GmbH&amp;rft.date=2010-01-14&amp;rft_id=http%3A%2F%2Fwww.bionity.com%2Fen%2Fnews%2F111706%2Fqiagen-acquires-ese-gmbh.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ipsogen-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-ipsogen_13-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.genomeweb.com/dxpgx/qiagen-plans-buy-cancer-mdx-firm-ipsogen-101m\">\"Qiagen Plans to Buy Cancer MDx Firm Ipsogen for $101M\"</a>. 15 Jun 2011.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Qiagen+Plans+to+Buy+Cancer+MDx+Firm+Ipsogen+for+%24101M&amp;rft.date=2011-06-15&amp;rft_id=https%3A%2F%2Fwww.genomeweb.com%2Fdxpgx%2Fqiagen-plans-buy-cancer-mdx-firm-ipsogen-101m&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-analyticalworld2011-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-analyticalworld2011_14-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.analytica-world.com/en/news/133014/qiagen-makes-proposal-to-fully-acquire-ipsogen.html\">\"QIAGEN makes proposal to fully acquire Ipsogen\"</a>. <i>analytica-world.com</i>. Germany: chemie.de. 16 June 2011. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140318005433/http://www.analytica-world.com/en/news/133014/qiagen-makes-proposal-to-fully-acquire-ipsogen.html\">Archived</a> from the original on 18 March 2014.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=analytica-world.com&amp;rft.atitle=QIAGEN+makes+proposal+to+fully+acquire+Ipsogen&amp;rft.date=2011-06-16&amp;rft_id=http%3A%2F%2Fwww.analytica-world.com%2Fen%2Fnews%2F133014%2Fqiagen-makes-proposal-to-fully-acquire-ipsogen.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.pharmafield.co.uk/medtech-news/2011/04/QIAGEN-acquires-Cellestis\">\"QIAGEN acquires Cellestis\"</a>. Medtech News. <i>Pharmaceutical Field</i>. United Kingdom: Health Sector Publishing. 2011. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140320040038/http://www.pharmafield.co.uk/medtech-news/2011/04/QIAGEN-acquires-Cellestis\">Archived</a> from the original on 19 March 2014.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmaceutical+Field&amp;rft.atitle=QIAGEN+acquires+Cellestis&amp;rft.date=2011&amp;rft_id=http%3A%2F%2Fwww.pharmafield.co.uk%2Fmedtech-news%2F2011%2F04%2FQIAGEN-acquires-Cellestis&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-streetinsider2011-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-streetinsider2011_16-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.streetinsider.com/Corporate+News/QIAGEN+%28QGEN%29+Launches+Productivity+Enhancement+Program%3B+8-10%25+of+Workforce+to+Be+Affected/6978746.html\">\"QIAGEN (QGEN) Launches Productivity Enhancement Program; 8-10% of Workforce to Be Affected\"</a>. <i>StreetInsider.com</i>. 28 November 2011. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20111230141119/http://www.streetinsider.com/Corporate+News/QIAGEN+%28QGEN%29+Launches+Productivity+Enhancement+Program%3B+8-10%25+of+Workforce+to+Be+Affected/6978746.html\">Archived</a> from the original on 30 December 2011.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=StreetInsider.com&amp;rft.atitle=QIAGEN+%28QGEN%29+Launches+Productivity+Enhancement+Program%3B+8-10%25+of+Workforce+to+Be+Affected&amp;rft.date=2011-11-28&amp;rft_id=http%3A%2F%2Fwww.streetinsider.com%2FCorporate%2BNews%2FQIAGEN%2B%2528QGEN%2529%2BLaunches%2BProductivity%2BEnhancement%2BProgram%253B%2B8-10%2525%2Bof%2BWorkforce%2Bto%2BBe%2BAffected%2F6978746.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.qiagen.com/landing-pages/qiagen-acquires-ingenuity-systems-2?intcmp=CC0513MCFIngenuityAcquistion\">\"QIAGEN acquires Ingenuity Systems\"</a>. 29 April 2013.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=QIAGEN+acquires+Ingenuity+Systems&amp;rft.date=2013-04-29&amp;rft_id=http%3A%2F%2Fwww.qiagen.com%2Flanding-pages%2Fqiagen-acquires-ingenuity-systems-2%3Fintcmp%3DCC0513MCFIngenuityAcquistion&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.qiagen.com/de/about-us/press-releases/pressreleaseview?ID={707D559F-CFA2-40C4-84B6-FBB5DFD5F9E5}&amp;lang=en\">\"QIAGEN acquires CLC bio - CLC bio\"</a>. <i>CLC bio</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-04-29</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=CLC+bio&amp;rft.atitle=QIAGEN+acquires+CLC+bio+-+CLC+bio&amp;rft_id=https%3A%2F%2Fwww.qiagen.com%2Fde%2Fabout-us%2Fpress-releases%2Fpressreleaseview%3FID%3D%7B707D559F-CFA2-40C4-84B6-FBB5DFD5F9E5%7D%26lang%3Den&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.genengnews.com/gen-news-highlights/qiagen-acquires-novel-circulating-tumor-cell-technology-for-liquid-biopsies/81251042/\">\"Qiagen Acquires Novel Circulating Tumor Cell Technology for Liquid Biopsies\"</a>. <i>GEN News</i>. Mar 17, 2015.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=GEN+News&amp;rft.atitle=Qiagen+Acquires+Novel+Circulating+Tumor+Cell+Technology+for+Liquid+Biopsies&amp;rft.date=2015-03-17&amp;rft_id=http%3A%2F%2Fwww.genengnews.com%2Fgen-news-highlights%2Fqiagen-acquires-novel-circulating-tumor-cell-technology-for-liquid-biopsies%2F81251042%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">QIAGEN. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.qiagen.com/de/about-us/press-releases/pressreleaseview?ID=%7BEF9BED88-B112-4F0E-B45C-82176D434BB2%7D&amp;lang=en\">\"QIAGEN - Sample to Insight\"</a>. <i>www.qiagen.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-04-29</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.qiagen.com&amp;rft.atitle=QIAGEN+-+Sample+to+Insight&amp;rft.au=QIAGEN&amp;rft_id=https%3A%2F%2Fwww.qiagen.com%2Fde%2Fabout-us%2Fpress-releases%2Fpressreleaseview%3FID%3D%257BEF9BED88-B112-4F0E-B45C-82176D434BB2%257D%26lang%3Den&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Staff (17 January 2018). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.clinicalomics.com/articles/haliodx-wins-22-6m-in-financing-toward-immunoscore-platform-u-s-expansion/1434\">\"HalioDx Wins $22.6M in Financing toward Immunoscore Platform, U.S. Expansion\"</a>. <i>Clinical OMICs</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">19 January</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+OMICs&amp;rft.atitle=HalioDx+Wins+%2422.6M+in+Financing+toward+Immunoscore+Platform%2C+U.S.+Expansion&amp;rft.date=2018-01-17&amp;rft.au=Staff&amp;rft_id=https%3A%2F%2Fwww.clinicalomics.com%2Farticles%2Fhaliodx-wins-22-6m-in-financing-toward-immunoscore-platform-u-s-expansion%2F1434&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">QIAGEN. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.qiagen.com/de/about-us/press-releases/pressreleaseview?ID=%7B8DD9BC4A-E3D3-4ED7-94F8-8D0BAB03856B%7D&amp;lang=en\">\"QIAGEN - Sample to Insight\"</a>. <i>www.qiagen.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-04-29</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.qiagen.com&amp;rft.atitle=QIAGEN+-+Sample+to+Insight&amp;rft.au=QIAGEN&amp;rft_id=https%3A%2F%2Fwww.qiagen.com%2Fde%2Fabout-us%2Fpress-releases%2Fpressreleaseview%3FID%3D%257B8DD9BC4A-E3D3-4ED7-94F8-8D0BAB03856B%257D%26lang%3Den&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">QIAGEN. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=%7b4E6CCD4B-05E4-4AFE-9C6A-C79E4333D983%7d&amp;lang=en\">\"QIAGEN announces successful completion of tender offer for shares in Exiqon\"</a>. <i>www.qiagen.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-09-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.qiagen.com&amp;rft.atitle=QIAGEN+announces+successful+completion+of+tender+offer+for+shares+in+Exiqon&amp;rft.au=QIAGEN&amp;rft_id=https%3A%2F%2Fwww.qiagen.com%2Fabout-us%2Fpress-releases%2Fpressreleaseview%3FID%3D%257b4E6CCD4B-05E4-4AFE-9C6A-C79E4333D983%257d%26lang%3Den&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.reuters.com/article/brief-qiagen-to-transfer-us-listing-of-g/brief-qiagen-to-transfer-u-s-listing-of-global-shares-to-nyse-idUSFWN1O80YK\">\"Qiagen To Transfer U.S. Listing Of Global Shares To Nyse\"</a>. <i>Reuters</i>. 14 February 2018<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">14 February</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Reuters&amp;rft.atitle=Qiagen+To+Transfer+U.S.+Listing+Of+Global+Shares+To+Nyse&amp;rft.date=2018-02-14&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fbrief-qiagen-to-transfer-us-listing-of-g%2Fbrief-qiagen-to-transfer-u-s-listing-of-global-shares-to-nyse-idUSFWN1O80YK&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Powell, Martha (23 April 2018). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.id-hub.com/2018/04/22/eccmid18-qiagen-announces-european-launch-platform-syndromic-insights-qiastat-dx/\">\"ECCMID18: QIAGEN announces European launch of platform for syndromic insights, QIAstat-Dx\"</a>. <i>Infectious Diseases Hub</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">28 June</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Infectious+Diseases+Hub&amp;rft.atitle=ECCMID18%3A+QIAGEN+announces+European+launch+of+platform+for+syndromic+insights%2C+QIAstat-Dx&amp;rft.date=2018-04-23&amp;rft.aulast=Powell&amp;rft.aufirst=Martha&amp;rft_id=https%3A%2F%2Fwww.id-hub.com%2F2018%2F04%2F22%2Feccmid18-qiagen-announces-european-launch-platform-syndromic-insights-qiastat-dx%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://corporate.qiagen.com/investor-relations/at-a-glance/strategy\">\"Fact Sheet: QIAGEN Strategy\"</a>. February 2018.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Fact+Sheet%3A+QIAGEN+Strategy&amp;rft.date=2018-02&amp;rft_id=http%3A%2F%2Fcorporate.qiagen.com%2Finvestor-relations%2Fat-a-glance%2Fstrategy&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">\"Trinean, Qiagen Enter into Global Supply Agreement\". News - Genomics &amp; Proteomics. <i><a href=\"/wiki/Gen._Eng._Biotechnol._News\" class=\"mw-redirect\" title=\"Gen. Eng. Biotechnol. News\">Gen. Eng. Biotechnol. News</a></i> (print). <b>34</b> (4). 15 February 2014. p.&#160;18.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gen.+Eng.+Biotechnol.+News&amp;rft.atitle=Trinean%2C+Qiagen+Enter+into+Global+Supply+Agreement&amp;rft.volume=34&amp;rft.issue=4&amp;rft.pages=18&amp;rft.date=2014-02-15&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">DiIulio, Renee (1 March 2006). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.clpmag.com/2006/03/molecular-diagnostics-challenges-and-benefits/\">\"Molecular Diagnostics: Challenges and Benefits\"</a>. <i>Clinical Lab Products</i>. United States. <a href=\"/wiki/OCLC\" title=\"OCLC\">OCLC</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/oclc/60626983\">60626983</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140320032101/http://www.clpmag.com/2006/03/molecular-diagnostics-challenges-and-benefits/\">Archived</a> from the original on 19 March 2014.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Lab+Products&amp;rft.atitle=Molecular+Diagnostics%3A+Challenges+and+Benefits&amp;rft.date=2006-03-01&amp;rft_id=info%3Aoclcnum%2F60626983&amp;rft.aulast=DiIulio&amp;rft.aufirst=Renee&amp;rft_id=http%3A%2F%2Fwww.clpmag.com%2F2006%2F03%2Fmolecular-diagnostics-challenges-and-benefits%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-29\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.qiagen.com/~/media/566323881F794A168ED9BAFB87374826.ashx\">\"Background Molecular Diagnostics\"</a>. December 2015.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Background+Molecular+Diagnostics&amp;rft.date=2015-12&amp;rft_id=https%3A%2F%2Fwww.qiagen.com%2F~%2Fmedia%2F566323881F794A168ED9BAFB87374826.ashx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-qiagenmgt-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-qiagenmgt_30-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://corporate.qiagen.com/about-us/Who-we-are/management/executive-committee\">\"Executive Committee\"</a>. QIAGEN. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://corporate.qiagen.com/about-us/Who-we-are/management/executive-committee\">the original</a> on 14 February 2018.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Executive+Committee&amp;rft.pub=QIAGEN&amp;rft_id=http%3A%2F%2Fcorporate.qiagen.com%2Fabout-us%2FWho-we-are%2Fmanagement%2Fexecutive-committee&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AQiagen\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n<div role=\"navigation\" class=\"navbox\" aria-labelledby=\"24px_TecDAX_companies_of_Germany_updated_18.03.2013\" style=\"padding:3px\"><table class=\"nowraplinks collapsible autocollapse navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:TecDAX_companies\" title=\"Template:TecDAX companies\"><abbr title=\"View this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:TecDAX_companies\" title=\"Template talk:TecDAX companies\"><abbr title=\"Discuss this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:TecDAX_companies&amp;action=edit\"><abbr title=\"Edit this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">e</abbr></a></li></ul></div><div id=\"24px_TecDAX_companies_of_Germany_updated_18.03.2013\" style=\"font-size:114%;margin:0 4em\"><a href=\"/wiki/File:Flag_of_Germany.svg\" class=\"image\"><img alt=\"Flag of Germany.svg\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/b/ba/Flag_of_Germany.svg/24px-Flag_of_Germany.svg.png\" width=\"24\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/b/ba/Flag_of_Germany.svg/36px-Flag_of_Germany.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/b/ba/Flag_of_Germany.svg/48px-Flag_of_Germany.svg.png 2x\" data-file-width=\"1000\" data-file-height=\"600\" /></a> <a href=\"/wiki/TecDAX\" title=\"TecDAX\">TecDAX</a> companies of Germany <small>updated 18.03.2013</small></div></th></tr><tr><td colspan=\"2\" class=\"navbox-list navbox-odd hlist\" style=\"width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/ADVA_Optical_Networking\" title=\"ADVA Optical Networking\">ADVA Optical Networking</a></li>\n<li><a href=\"/wiki/Aixtron\" title=\"Aixtron\">Aixtron</a></li>\n<li><a href=\"/wiki/BB_Biotech\" title=\"BB Biotech\">BB Biotech</a></li>\n<li><a href=\"/wiki/Bechtle\" title=\"Bechtle\">Bechtle</a></li>\n<li><a href=\"/w/index.php?title=Cancom_AG&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Cancom AG (page does not exist)\">Cancom AG</a></li>\n<li><a href=\"/wiki/Carl_Zeiss_Meditec\" title=\"Carl Zeiss Meditec\">Carl Zeiss Meditec</a></li>\n<li><a href=\"/wiki/Dialog_Semiconductor\" title=\"Dialog Semiconductor\">Dialog Semiconductor</a></li>\n<li><a href=\"/wiki/Dr%C3%A4gerwerk\" title=\"Dr\u00e4gerwerk\">Dr\u00e4gerwerk</a></li>\n<li><a href=\"/wiki/Drillisch\" title=\"Drillisch\">Drillisch</a></li>\n<li><a href=\"/w/index.php?title=Euromicron&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Euromicron (page does not exist)\">Euromicron</a></li>\n<li><a href=\"/w/index.php?title=Evotec&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Evotec (page does not exist)\">Evotec</a></li>\n<li><a href=\"/wiki/Freenet_AG\" title=\"Freenet AG\">Freenet AG</a></li>\n<li><a href=\"/wiki/Jenoptik\" title=\"Jenoptik\">Jenoptik</a></li>\n<li><a href=\"/wiki/Kontron\" title=\"Kontron\">Kontron</a></li>\n<li><a href=\"/wiki/LPKF_Laser_%26_Electronics\" title=\"LPKF Laser &amp; Electronics\">LPKF Laser &amp; Electronics</a></li>\n<li><a href=\"/wiki/MorphoSys\" title=\"MorphoSys\">MorphoSys</a></li>\n<li><a href=\"/wiki/Nordex_SE\" class=\"mw-redirect\" title=\"Nordex SE\">Nordex SE</a></li>\n<li><a href=\"/wiki/Pfeiffer_Vacuum\" title=\"Pfeiffer Vacuum\">Pfeiffer Vacuum</a></li>\n<li><a href=\"/w/index.php?title=PSI_AG&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"PSI AG (page does not exist)\">PSI AG</a></li>\n<li><a class=\"mw-selflink selflink\">Qiagen</a></li>\n<li><a href=\"/wiki/QSC_AG\" title=\"QSC AG\">QSC AG</a></li>\n<li><a href=\"/wiki/Sartorius_AG\" title=\"Sartorius AG\">Sartorius AG</a></li>\n<li><a href=\"/wiki/SMA_Solar_Technology\" title=\"SMA Solar Technology\">SMA Solar Technology</a></li>\n<li><a href=\"/wiki/Software_AG\" title=\"Software AG\">Software AG</a></li>\n<li><a href=\"/wiki/Stratec_Biomedical_Systems\" title=\"Stratec Biomedical Systems\">Stratec Biomedical Systems</a></li>\n<li><a href=\"/wiki/SUSS_MicroTec\" title=\"SUSS MicroTec\">S\u00fcss MicroTec</a></li>\n<li><a href=\"/wiki/Telef%C3%B3nica_Germany\" title=\"Telef\u00f3nica Germany\">Telef\u00f3nica Germany</a></li>\n<li><a href=\"/wiki/United_Internet\" title=\"United Internet\">United Internet</a></li>\n<li><a href=\"/wiki/Wirecard\" title=\"Wirecard\">Wirecard</a></li>\n<li><a href=\"/wiki/XING\" title=\"XING\">XING</a></li></ul>\n</div></td></tr></tbody></table></div>\n\n<!-- \nNewPP limit report\nParsed by mw1262\nCached time: 20180908211450\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.480 seconds\nReal time usage: 0.569 seconds\nPreprocessor visited node count: 3961/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 104854/2097152 bytes\nTemplate argument size: 16171/2097152 bytes\nHighest expansion depth: 17/40\nExpensive parser function count: 3/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 28499/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.253/10.000 seconds\nLua memory usage: 6.29 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  494.505      1 -total\n 28.06%  138.748     16 Template:CN\n 24.36%  120.440     16 Template:Fix\n 21.04%  104.063      3 Template:Ambox\n 19.03%   94.083      1 Template:Infobox_company\n 17.17%   84.920      1 Template:Multiple_issues\n 17.07%   84.412      1 Template:Infobox\n 13.66%   67.550     16 Template:Delink\n 11.91%   58.887     15 Template:Cite_news\n  8.90%   44.002     32 Template:Category_handler\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:3283783-0!canonical and timestamp 20180908211449 and revision id 847903468\n -->\n</div>"},"langlinks":[{"lang":"de","url":"https://de.wikipedia.org/wiki/Qiagen","langname":"German","autonym":"Deutsch","*":"Qiagen"},{"lang":"fr","url":"https://fr.wikipedia.org/wiki/Qiagen","langname":"French","autonym":"fran\u00e7ais","*":"Qiagen"},{"lang":"ru","url":"https://ru.wikipedia.org/wiki/Qiagen","langname":"Russian","autonym":"\u0440\u0443\u0441\u0441\u043a\u0438\u0439","*":"Qiagen"}],"categories":[{"sortkey":"","hidden":"","*":"Articles_with_a_promotional_tone_from_November_2010"},{"sortkey":"","hidden":"","*":"All_articles_with_a_promotional_tone"},{"sortkey":"","hidden":"","*":"Articles_needing_additional_references_from_May_2011"},{"sortkey":"","hidden":"","*":"All_articles_needing_additional_references"},{"sortkey":"","hidden":"","*":"Articles_with_multiple_maintenance_issues"},{"sortkey":"","hidden":"","*":"Pages_using_deprecated_image_syntax"},{"sortkey":"","hidden":"","*":"All_articles_with_unsourced_statements"},{"sortkey":"","hidden":"","*":"Articles_with_unsourced_statements_from_March_2018"},{"sortkey":"","*":"Medical_software"},{"sortkey":"","*":"Research_support_companies"},{"sortkey":"","*":"Companies_based_in_North_Rhine-Westphalia"},{"sortkey":"","*":"Companies_established_in_1984"},{"sortkey":"","*":"Companies_listed_on_the_New_York_Stock_Exchange"}],"links":[{"ns":14,"exists":"","*":"Category:Articles with a promotional tone from November 2010"},{"ns":14,"exists":"","*":"Category:Articles needing additional references from May 2011"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from March 2018"},{"ns":10,"exists":"","*":"Template:TecDAX companies"},{"ns":0,"exists":"","*":"2009 flu pandemic"},{"ns":0,"exists":"","*":"ADVA Optical Networking"},{"ns":0,"exists":"","*":"Aixtron"},{"ns":0,"exists":"","*":"Asset"},{"ns":0,"exists":"","*":"BB Biotech"},{"ns":0,"exists":"","*":"Bechtle"},{"ns":0,"exists":"","*":"BioTechniques"},{"ns":0,"exists":"","*":"Biotechnology"},{"ns":0,"exists":"","*":"CLC bio"},{"ns":0,"exists":"","*":"Carl Zeiss Meditec"},{"ns":0,"exists":"","*":"Chairman"},{"ns":0,"exists":"","*":"Chief executive officer"},{"ns":0,"exists":"","*":"ChinaDaily"},{"ns":0,"exists":"","*":"Column-based nucleic acid purification"},{"ns":0,"exists":"","*":"DNA"},{"ns":0,"exists":"","*":"Dialog Semiconductor"},{"ns":0,"exists":"","*":"Digene"},{"ns":0,"exists":"","*":"Drillisch"},{"ns":0,"exists":"","*":"Dr\u00e4gerwerk"},{"ns":0,"exists":"","*":"D\u00fcsseldorf"},{"ns":0,"exists":"","*":"Earnings before interest and taxes"},{"ns":0,"exists":"","*":"Equity (finance)"},{"ns":0,"exists":"","*":"Frankfurt Stock Exchange"},{"ns":0,"exists":"","*":"Freenet AG"},{"ns":0,"exists":"","*":"Gen. Eng. Biotechnol. News"},{"ns":0,"exists":"","*":"Germany"},{"ns":0,"exists":"","*":"Hilden"},{"ns":0,"exists":"","*":"India"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"Jenoptik"},{"ns":0,"exists":"","*":"Kontron"},{"ns":0,"exists":"","*":"LPKF Laser & Electronics"},{"ns":0,"exists":"","*":"List of business entities"},{"ns":0,"exists":"","*":"Management buyout"},{"ns":0,"exists":"","*":"Maryland"},{"ns":0,"exists":"","*":"MorphoSys"},{"ns":0,"exists":"","*":"NASDAQ"},{"ns":0,"exists":"","*":"NYSE"},{"ns":0,"exists":"","*":"Naamloze vennootschap"},{"ns":0,"exists":"","*":"Netherlands"},{"ns":0,"exists":"","*":"New Delhi"},{"ns":0,"exists":"","*":"New York Stock Exchange"},{"ns":0,"exists":"","*":"Nordex SE"},{"ns":0,"exists":"","*":"OCLC"},{"ns":0,"exists":"","*":"Peer M. Schatz"},{"ns":0,"exists":"","*":"Pfeiffer Vacuum"},{"ns":0,"exists":"","*":"Plasmid"},{"ns":0,"exists":"","*":"Plasmids"},{"ns":0,"exists":"","*":"Proteins"},{"ns":0,"exists":"","*":"QSC AG"},{"ns":0,"exists":"","*":"RNA"},{"ns":0,"exists":"","*":"Russell 1000 Index"},{"ns":0,"exists":"","*":"SMA Solar Technology"},{"ns":0,"exists":"","*":"SUSS MicroTec"},{"ns":0,"exists":"","*":"Sartorius AG"},{"ns":0,"exists":"","*":"Shanghai"},{"ns":0,"exists":"","*":"Software AG"},{"ns":0,"exists":"","*":"Spectrophotometer"},{"ns":0,"exists":"","*":"Stratec Biomedical Systems"},{"ns":0,"exists":"","*":"Supervisory board"},{"ns":0,"exists":"","*":"Supply agreement"},{"ns":0,"exists":"","*":"Taipei"},{"ns":0,"exists":"","*":"Taiwan"},{"ns":0,"exists":"","*":"TecDAX"},{"ns":0,"exists":"","*":"Telef\u00f3nica Germany"},{"ns":0,"exists":"","*":"Ticker symbol"},{"ns":0,"exists":"","*":"United Internet"},{"ns":0,"exists":"","*":"University of D\u00fcsseldorf"},{"ns":0,"exists":"","*":"Venlo"},{"ns":0,"exists":"","*":"Wirecard"},{"ns":0,"exists":"","*":"XING"},{"ns":0,"*":"Cancom AG"},{"ns":0,"*":"Euromicron"},{"ns":0,"*":"Evotec"},{"ns":0,"*":"PSI AG"},{"ns":1,"exists":"","*":"Talk:Qiagen"},{"ns":4,"exists":"","*":"Wikipedia:Citation needed"},{"ns":4,"exists":"","*":"Wikipedia:External links"},{"ns":4,"exists":"","*":"Wikipedia:Neutral point of view"},{"ns":4,"exists":"","*":"Wikipedia:Spam"},{"ns":4,"exists":"","*":"Wikipedia:Verifiability"},{"ns":4,"exists":"","*":"Wikipedia:What Wikipedia is not"},{"ns":11,"exists":"","*":"Template talk:TecDAX companies"},{"ns":12,"exists":"","*":"Help:Introduction to referencing with Wiki Markup/1"},{"ns":12,"exists":"","*":"Help:Maintenance template removal"}],"templates":[{"ns":10,"exists":"","*":"Template:Multiple issues"},{"ns":10,"exists":"","*":"Template:Ambox"},{"ns":10,"exists":"","*":"Template:Advert"},{"ns":10,"exists":"","*":"Template:Refimprove"},{"ns":10,"exists":"","*":"Template:More citations needed"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Infobox company"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:Longitem"},{"ns":10,"exists":"","*":"Template:NYSE"},{"ns":10,"exists":"","*":"Template:New York Stock Exchange"},{"ns":10,"exists":"","*":"Template:FWB"},{"ns":10,"exists":"","*":"Template:Frankfurt Stock Exchange"},{"ns":10,"exists":"","*":"Template:Br separated entries"},{"ns":10,"exists":"","*":"Template:Start date and age"},{"ns":10,"exists":"","*":"Template:Yesno"},{"ns":10,"exists":"","*":"Template:MONTHNAME"},{"ns":10,"exists":"","*":"Template:MONTHNUMBER"},{"ns":10,"exists":"","*":"Template:Time ago"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Comma separated entries"},{"ns":10,"exists":"","*":"Template:Nowrap"},{"ns":10,"exists":"","*":"Template:Url"},{"ns":10,"exists":"","*":"Template:URL"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:CN"},{"ns":10,"exists":"","*":"Template:Citation needed"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:For"},{"ns":10,"exists":"","*":"Template:Cite book"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:TecDAX companies"},{"ns":10,"exists":"","*":"Template:Navbox"},{"ns":828,"exists":"","*":"Module:Message box"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Message box/configuration"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:String"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:Stock tickers/NYSE"},{"ns":828,"exists":"","*":"Module:Separated entries"},{"ns":828,"exists":"","*":"Module:TableTools"},{"ns":828,"exists":"","*":"Module:TimeAgo"},{"ns":828,"exists":"","*":"Module:NumberSpell"},{"ns":828,"exists":"","*":"Module:URL"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:For"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Navbox"}],"images":["Ambox_important.svg","Question_book-new.svg","Qiagen.svg","Flag_of_Germany.svg"],"externallinks":["http://corporate.qiagen.com/about-us","http://www.genomeweb.com/dxpgx/qiagen-acquires-uks-dxs-deal-worth-130m","https://web.archive.org/web/20110320104914/http://www.genomeweb.com/dxpgx/qiagen-acquires-uks-dxs-deal-worth-130m","https://web.archive.org/web/20140320033732/http://www.biotechniques.com/news/biotechniquesNews/biotechniques-185334.html","http://www.biotechniques.com/news/biotechniquesNews/biotechniques-185334.html","http://www.chinadaily.com.cn/cndy/2009-09/12/content_8684608.htm","https://web.archive.org/web/20140320034515/http://www.chinadaily.com.cn/cndy/2009-09/12/content_8684608.htm","http://www.bionity.com/en/news/111706/qiagen-acquires-ese-gmbh.html","https://web.archive.org/web/20140320035423/http://www.bionity.com/en/news/111706/qiagen-acquires-ese-gmbh.html","https://www.genomeweb.com/dxpgx/qiagen-plans-buy-cancer-mdx-firm-ipsogen-101m","http://www.analytica-world.com/en/news/133014/qiagen-makes-proposal-to-fully-acquire-ipsogen.html","https://web.archive.org/web/20140318005433/http://www.analytica-world.com/en/news/133014/qiagen-makes-proposal-to-fully-acquire-ipsogen.html","http://www.pharmafield.co.uk/medtech-news/2011/04/QIAGEN-acquires-Cellestis","https://web.archive.org/web/20140320040038/http://www.pharmafield.co.uk/medtech-news/2011/04/QIAGEN-acquires-Cellestis","http://www.streetinsider.com/Corporate+News/QIAGEN+(QGEN)+Launches+Productivity+Enhancement+Program;+8-10%25+of+Workforce+to+Be+Affected/6978746.html","https://web.archive.org/web/20111230141119/http://www.streetinsider.com/Corporate+News/QIAGEN+(QGEN)+Launches+Productivity+Enhancement+Program;+8-10%25+of+Workforce+to+Be+Affected/6978746.html","http://www.qiagen.com/landing-pages/qiagen-acquires-ingenuity-systems-2?intcmp=CC0513MCFIngenuityAcquistion","https://www.qiagen.com/de/about-us/press-releases/pressreleaseview?ID=%7B707D559F-CFA2-40C4-84B6-FBB5DFD5F9E5%7D&lang=en","http://www.genengnews.com/gen-news-highlights/qiagen-acquires-novel-circulating-tumor-cell-technology-for-liquid-biopsies/81251042/","https://www.qiagen.com/de/about-us/press-releases/pressreleaseview?ID=%7BEF9BED88-B112-4F0E-B45C-82176D434BB2%7D&lang=en","https://www.clinicalomics.com/articles/haliodx-wins-22-6m-in-financing-toward-immunoscore-platform-u-s-expansion/1434","https://www.qiagen.com/de/about-us/press-releases/pressreleaseview?ID=%7B8DD9BC4A-E3D3-4ED7-94F8-8D0BAB03856B%7D&lang=en","https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=%7B4E6CCD4B-05E4-4AFE-9C6A-C79E4333D983%7D&lang=en","https://www.reuters.com/article/brief-qiagen-to-transfer-us-listing-of-g/brief-qiagen-to-transfer-u-s-listing-of-global-shares-to-nyse-idUSFWN1O80YK","https://www.id-hub.com/2018/04/22/eccmid18-qiagen-announces-european-launch-platform-syndromic-insights-qiastat-dx/","http://corporate.qiagen.com/investor-relations/at-a-glance/strategy","http://www.clpmag.com/2006/03/molecular-diagnostics-challenges-and-benefits/","//www.worldcat.org/oclc/60626983","https://web.archive.org/web/20140320032101/http://www.clpmag.com/2006/03/molecular-diagnostics-challenges-and-benefits/","https://www.qiagen.com/~/media/566323881F794A168ED9BAFB87374826.ashx","http://corporate.qiagen.com/about-us/Who-we-are/management/executive-committee","https://www.qiagen.com/be/about-us/investors/corporate-governance/supervisory-board/","https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_q4fy2018_results","https://www.qiagen.com/be/about-us/investors/financial-information/key-figures/","https://www.nyse.com/quote/XNYS:QGEN","http://www.boerse-frankfurt.de/en/equities/search/result?name_isin_wkn=QIA","http://www.qiagen.com"],"sections":[{"toclevel":1,"level":"2","line":"History","number":"1","index":"1","fromtitle":"Qiagen","byteoffset":2652,"anchor":"History"},{"toclevel":2,"level":"3","line":"1984-2000","number":"1.1","index":"2","fromtitle":"Qiagen","byteoffset":2666,"anchor":"1984-2000"},{"toclevel":2,"level":"3","line":"2001-present","number":"1.2","index":"3","fromtitle":"Qiagen","byteoffset":3588,"anchor":"2001-present"},{"toclevel":1,"level":"2","line":"Products","number":"2","index":"4","fromtitle":"Qiagen","byteoffset":12462,"anchor":"Products"},{"toclevel":1,"level":"2","line":"Application areas","number":"3","index":"5","fromtitle":"Qiagen","byteoffset":13911,"anchor":"Application_areas"},{"toclevel":2,"level":"3","line":"Molecular diagnostics","number":"3.1","index":"6","fromtitle":"Qiagen","byteoffset":14225,"anchor":"Molecular_diagnostics"},{"toclevel":2,"level":"3","line":"Applied testing","number":"3.2","index":"7","fromtitle":"Qiagen","byteoffset":17197,"anchor":"Applied_testing"},{"toclevel":2,"level":"3","line":"Academic research","number":"3.3","index":"8","fromtitle":"Qiagen","byteoffset":17919,"anchor":"Academic_research"},{"toclevel":2,"level":"3","line":"Pharmaceutical industry","number":"3.4","index":"9","fromtitle":"Qiagen","byteoffset":18659,"anchor":"Pharmaceutical_industry"},{"toclevel":1,"level":"2","line":"Management","number":"4","index":"10","fromtitle":"Qiagen","byteoffset":19440,"anchor":"Management"},{"toclevel":1,"level":"2","line":"Structure of the company","number":"5","index":"11","fromtitle":"Qiagen","byteoffset":20368,"anchor":"Structure_of_the_company"},{"toclevel":1,"level":"2","line":"References","number":"6","index":"12","fromtitle":"Qiagen","byteoffset":20713,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Qiagen","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q315287"}]}}